Tokyo, Nov. 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059796) titled 'A Cross-sectional Study on the Duration of Gardenia jasminoides (Sanshishi)-containing Kampo Extract Use and Related Background Factors among Outpatients at Our Institution' on Nov. 17.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu University
Condition:
Condition - Diseases generally indicated for Kampo extract preparations containing Gardenia jasminoides (Sanshishi)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to clarify a part of the real-world prescription status of Kampo extract preparations containing Gardenia jasminoides (Sanshishi) by conducting a cross-sectional survey on the duration of use of Gardenia-containing Kampo formulations among patients prescribed Kampo extract preparations.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who visited Shinshu University Hospital between April 1, 2017, and March 31, 2025, and were prescribed Kampo extract preparations in the outpatient clinic.
Key exclusion criteria - None.
Target Size - 200
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 14 Day
Date of IRB - 2025 Year 10 Month 27 Day
Anticipated trial start date - 2025 Year 11 Month 17 Day
Last follow-up date - 2026 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068008
Disclaimer: Curated by HT Syndication.
